<SEC-DOCUMENT>0001213900-21-008389.txt : 20210211
<SEC-HEADER>0001213900-21-008389.hdr.sgml : 20210211
<ACCEPTANCE-DATETIME>20210211132952
ACCESSION NUMBER:		0001213900-21-008389
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210205
FILED AS OF DATE:		20210211
DATE AS OF CHANGE:		20210211

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Rhodes Jason P
		CENTRAL INDEX KEY:			0001577014

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39438
		FILM NUMBER:		21618396

	MAIL ADDRESS:	
		STREET 1:		C/O EPIZYME, INC.
		STREET 2:		400 TECHNOLOGY SQUARE, 4TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemini Therapeutics, Inc. /DE
		CENTRAL INDEX KEY:			0001816736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851613057
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		300 ONE KENDALL SQUARE, 3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		(617) 401-4400

	MAIL ADDRESS:	
		STREET 1:		300 ONE KENDALL SQUARE, 3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FS Development Corp.
		DATE OF NAME CHANGE:	20200702
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-02-05</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001816736</issuerCik>
        <issuerName>Gemini Therapeutics, Inc. /DE</issuerName>
        <issuerTradingSymbol>GMTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001577014</rptOwnerCik>
            <rptOwnerName>Rhodes Jason P</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>300 TECHNOLOGY SQ, 8TH FLOOR</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE,</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02139</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4015045</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>729320</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>510000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents 4,744,365 shares issued as Merger Consideration pursuant to the Merger Agreement. Atlas Venture Associates X, L.P. (&quot;Atlas X LP&quot;) is the general partner of Atlas Fund X, and Atlas Venture Associates X, LLC (&quot;Atlas X LLC&quot;) is the general partner of Atlas X LP. Each of Atlas Fund X, Atlas X LP. and Atlas X LLC may be deemed to beneficially own the shares held by Atlas Fund X. Each of Atlas X LP and Atlas X LLC disclaim Section 16 beneficial ownership of the securities owned by Atlas Fund X. Atlas Venture Associates Opportunity I, L.P. (&quot;Atlas I LP&quot;) is the general partner of Atlas Fund I, and Atlas Venture Associates Opportunity I, LLC (&quot;AVAO, LLC&quot;) is the general partner of Atlas I LP. Each of Atlas Fund I, Atlas I LP and AVAO LLC may be deemed to beneficially own the shares held by Atlas Fund I. Each of Atlas I LP and AVAO LLC disclaim Section 16 beneficial ownership of the securities owned by Atlas Fund I.</footnote>
        <footnote id="F2">Represents 510,000 shares issued in the private placement of public securities (&quot;PIPE&quot;) on February 5, 2021 to Atlas Venture Fund XII, L.P. (&quot;Atlas Fund XII&quot;). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. (&quot;AVA XII LP&quot;). Atlas Venture Associates XII, LLC (&quot;AVA XII LLC&quot;) is the general partner of AVA XII LP. Bruce Booth, Jean- Francois Formela, David Grayzel, Jason Rhodes, Michael Gladstone and Kevin Bitterman are the members of Atlas XII LLC and collectively make investment decisions on behalf of Atlas XII LLC. Each of Atlas Fund XII, AVA XII LP, and AVA XII LLC may be deemed to beneficially own the shares held by Atlas Fund XII. Jason Rhodes is also a member of our board of directors. Mr. Rhodes disclaims beneficial ownership of the shares listed, except to the extent of his pecuniary interest therein, if any.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Ommer Chohan By: Ommer Chohan, attorney-in-fact</signatureName>
        <signatureDate>2021-02-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
